Kineta Inc. Announces Enrollment Of First Subject In 1B Clinical Trial

SEATTLE--(BUSINESS WIRE)--Kineta, Inc., a biotechnology company focused on the development of immune modulating drugs for critical disease areas, announced today that it has enrolled the first subject in a U.S. Phase 1B clinical trial of its lead drug, ShK-186, a novel immune-sparing therapeutic in development for a variety of autoimmune diseases. A successful Phase 1A safety trial was completed in March.

Help employers find you! Check out all the jobs and post your resume.